Nurix Therapeutics, Inc.NRIXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -12.37% | +11.26% | +264.34% | -37.29% | +2.21% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +43.42% | +52.20% | +34.48% | +15.64% | +21.27% |
| Weighted Average Shares Diluted Growth | +43.42% | +52.20% | +34.48% | +15.64% | +21.27% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -282.66% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -310.99% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +87.50% | -100.00% | +3066.67% | -100.00% | -100.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +88.23% | +96.70% | +15.76% | +1.73% | +2.81% |
| Book Value per Share Growth | +83.27% | +87.25% | -10.21% | -14.58% | -15.70% |
| Debt Growth | -7.55% | -8.69% | +80.20% | +108.11% | +96.90% |
| R&D Expense Growth | +35.22% | +39.31% | +59.63% | +55.22% | +20.35% |
| SG&A Expenses Growth | -0.58% | -1.23% | +21.96% | +12.30% | +27.35% |